Longyao Biotech is committed to developing tumor immunocyte technology, stem cell technology, cell storage technology and anti‑aging technologies. The company completed its first financing round of nearly ¥100 million, with a pre‑money valuation of about ¥800 million. The round was described as a strategic investment led by Yixing Huan Keyuan Industrial Park Development Equity Investment Partnership. Controlling shareholder China Biotechnology Service increased its investment in this round. The financing is intended to support the company's development across cell therapies and biobanking technologies. The article does not disclose operating metrics such as revenue or user counts.

Total raised

$14M

Funding rounds

1

Latest round

Equity

Latest activity

Dec 2023